Seizinger Bernd R.
SEC insider (Form 3/4/5 filer). CIK 0001789042. Insider at Aptose Biosciences Inc. (APTO) and 2 other issuers. 8 reported Form 4/5 transactions since Sep 2024; latest on Jun 30, 2026. Located in TORONTO.
Companies Seizinger Bernd R. has filed insider reports for
- Aptose Biosciences Inc. (APTO)
- Aprea Therapeutics, Inc. (APRE): Director
- ONCOLYTICS BIOTECH INC (ONCY): Director
Seizinger Bernd R.
CIK: 0001789042
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 30, 2026APTO
Aptose Biosciences Inc.
DispositionDirect17K shares at avg. $1.72$29K - Jun 16, 2026APRE
Aprea Therapeutics, Inc.
AwardDirect3.1K shares- - Jun 1, 2026ONCY
ONCOLYTICS BIOTECH INC
AwardDirectStock Option
30K shares- - Feb 12, 2026ONCY
ONCOLYTICS BIOTECH INC
PurchaseDirect40K shares at avg. $0.85$34K - Feb 11, 2026ONCY
ONCOLYTICS BIOTECH INC
PurchaseDirect60K shares at avg. $0.83$50K - Jan 16, 2026ONCY
ONCOLYTICS BIOTECH INC
PurchaseDirect100K shares at avg. $1.04$104K - Jun 5, 2025APRE
Aprea Therapeutics, Inc.
AwardDirect1K shares- - Oct 11, 2024APRE
Aprea Therapeutics, Inc.
PurchaseDirect10K shares at avg. $2.68$27K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 |  APTO Aptose Biosciences Inc. | Disposition | 17,000 | $1.72 | $29,240 | Direct |
| Jun 16, 2026 |  APRE Aprea Therapeutics, Inc. | Award | 3,135 | - | $0 | Direct |
| Jun 1, 2026 |  ONCY ONCOLYTICS BIOTECH INC | Award Stock Option | 30,000 | - | - | Direct |
| Feb 12, 2026 | ONCY ONCOLYTICS BIOTECH INC | Purchase | 40,000 | $0.85 | $33,864 | Direct |
| Feb 11, 2026 | ONCY ONCOLYTICS BIOTECH INC | Purchase | 60,000 | $0.83 | $49,590 | Direct |
| Jan 16, 2026 | ONCY ONCOLYTICS BIOTECH INC | Purchase | 100,000 | $1.04 | $103,770 | Direct |
| Jun 5, 2025 | APRE Aprea Therapeutics, Inc. | Award | 1,045 | - | - | Direct |
| Oct 11, 2024 | APRE Aprea Therapeutics, Inc. | Purchase | 10,000 | $2.68 | $26,800 | Direct |
1-8 of 8 transactions